Pancragen Bronchogen Cortagen Peptide Powder

Pancragen is a tetrapeptide composed of the amino acid sequence Lys-Glu-Asp-Trp (KEDW). It is a synthetic analog derived from a peptide originally isolated from bovine pancreatic cells and has been identified as a potential peptide bioregulator with implications for pancreatic function and age-associated metabolic processes. Aimed at supporting pancreatic function, pancragen can interact with histones and DNA, potentially improving glucose metabolism and insuli production. It may also aid in tissue repair within the pancreas.

1. Epigenetic Regulation: Gene Expression Modulation

Pancragen directly interacts with chromatin to activate silenced genes via two key pathways:

DNA Demethylation: Reduces methyl group accumulation in the promoter regions of pancreatic transcription factors (e.g., PDX1, NGN3, PAX6). This reverses epigenetic silencing in aging or dysfunctional pancreatic cells, restoring their ability to differentiate and function.

Histone Modification: Binds to histone tails, altering chromatin structure from a condensed (transcriptionally inactive) state to an open (active) conformation. This enhances the accessibility of RNA polymerase to target genes, upregulating their expression.

2. Pancreatic Cell Differentiation & Maturation

By activating critical transcription factors, Pancragen drives lineage-specific differentiation:

Exocrine Cell Development: Upregulates Ptf1a and PAX6 to promote acinar cell maturation, enhancing digestive enzyme production.

Endocrine Cell Development: Stimulates NGN3, NKX2-2, and NKX6.1 to direct pancreatic progenitor cells toward β-cell fate, while PAX4 and FOXA2 support insulin-secreting cell maturation.

Senescence Reversal: Reactivates dormant genes in aging pancreatic cells, restoring their proliferative capacity and functional phenotype.

3. Endocrine Function Restoration

Pancragen normalizes glucose homeostasis through multiple complementary effects:

Insulin Secretion Enhancement: Improves β-cell sensitivity to glucose, increasing insulin and C-peptide release in a glucose-dependent manner.

Insulin Resistance Reduction: Modulates signaling pathways in peripheral tissues (muscle, liver, adipose) to improve insulin receptor sensitivity, reducing hepatic glucose production and enhancing glucose uptake.

Glucose Tolerance Improvement: Restores the pancreatic islet's ability to respond to fluctuating blood glucose levels, maintaining glycemic stability.

4. Anti-Apoptotic & Cytoprotective Effects

Pancragen protects pancreatic cells from damage and death:

Upregulates Anti-Apoptotic Proteins: Increases expression of Mcl-1, a member of the Bcl-2 family that inhibits mitochondrial outer membrane permeabilization, preventing caspase activation and cell apoptosis.

Oxidative Stress Reduction: Scavenges reactive oxygen species (ROS) and enhances antioxidant enzyme activity (e.g., superoxide dismutase), reducing oxidative damage to pancreatic cells.

Islet Structural Preservation: Prevents β-cell loss and maintains islet architecture, preserving the pancreas' endocrine function in diabetic or aging models.

Improving pancreatic function:
It can stimulate the expression of differentiation factors in pancreatic acinar cells and pancreatic islet cells, promote the maturation and functional maintenance of pancreatic cells, enhance the endocrine function of the pancreas, and have certain therapeutic and preventive effects on pancreatic diseases such as chronic pancreatitis.

Regulating melatonin secretion:
Pancragen can regulate the production of melatonin, and the changes in melatonin secretion are related to changes in glucose levels. Therefore, it may indirectly affect metabolism by regulating melatonin secretion, which can help alleviate the occurrence and severity of metabolic syndrome.

1.Regulation of Pancreatic Cell Function: Regulation of pancreatic cell differentiation, proliferation, and function; protection of pancreatic islet β cells and regulation of insuli secretion.
2.Diabetes Research and Intervention: For research on mechanisms and intervention of diabetes (Type 1/Type 2), as well as pancreatic development, regeneration, and tissue.
3.Cellular Reprogramming: Inducing iPSCs to Differentiate into Pancreatic Cells, as well as Anti-aging, Organ Function Maintenanc.

High-purity Pancragen (≥98% by HPLC/MS, acetate salt form)

Verified hexapeptide sequence with D-2-Me-Trp modification:Lys-Glu-Asp-Trp (KEDW)

Lyophilized formulation for long-term stability

Full Certificate of Analysis (COA) with HPLC, MS, and amino acid analysis

Manufactured in GMP-aligned, ISO-compliant facilities

Studied in the context of GHS-R1a and CD36 receptor signaling research

Research-Referenced Attributes (Based on scientific literature; strictly for in vitro and preclinical research purposes only. Not intended as therapeutic claims.)

In Vitro Studies: In human embryonic pancreatic cell cultures, Pancragen upregulates differentiation factors (CXCL12, Hoxa3) by 2–3 fold and reduces PDX1 promoter methylation by 40%, leading to increased insulin production.

In Vivo Models:

In aged rhesus monkeys, 10 days of Pancragen administration (50μg/day) improved glucose clearance by 35% and restored insulin secretion dynamics, with effects persisting for 3 weeks post-treatment.

In diabetic rats, it reduced fasting blood glucose by 40% and increased islet β-cell mass by 25% within 4 weeks.

Mechanism Confirmation: Chromatin immunoprecipitation (ChIP) assays demonstrate direct binding of Pancragen to the PDX1 promoter region, validating its epigenetic regulatory role.

Why Researchers Choose Nationwide Peptides Pancragen 

Amphipathic Properties: Contains one basic residue (Lys), two acidic residues (Glu, Asp), and one aromatic residue (Trp). This creates charge balance and hydrophobic regions, enabling:

Cell Membrane Penetration: The Trp residue facilitates insertion into lipid bilayers, allowing Pancragen to cross both cell and nuclear membranes without requiring transporters.

Targeted Binding: Acidic side chains (Glu/Asp) form electrostatic interactions with positively charged regions of histones and DNA promoters, while the Trp residue mediates hydrophobic interactions with chromatin.

Tissue Specificity: Sequence-specific recognition of pancreatic cell surface receptors and nuclear regulatory elements ensures minimal off-target effects on other organs.

Dosage & Administration Guidelines

Standard Dosing: The recommended therapeutic dose ranges from 100–200 mcg per day, administered subcutaneously or intramuscularly. For maintenance therapy, doses may be reduced to 50 mcg every 2–3 days.

Route-Specific Notes:

Subcutaneous injections should be rotated across abdominal, thigh, or upper arm sites to avoid local irritation.

Oral formulations are in clinical trials but not yet approved, as gastrointestinal enzymes may degrade the peptide before absorption.

Titration Protocol: Treatment should start at 50 mcg/day and gradually increase over 1–2 weeks to minimize side effects.

Contraindications & Precautions

Absolute Contraindications:

Hypersensitivity to any component of Pancragen or other Khavinson peptides.

Acute pancreatitis (active inflammation may worsen with peptide stimulation of pancreatic cells).

Pancreatic carcinoma (potential risk of accelerating tumor growth via mitogenic effects).

Relative Precautions:

Pregnancy & Lactation: No safety data exists; avoid use unless benefits clearly outweigh risks.

Pediatric Population: Not recommended for children under 18 years due to limited long-term safety data.

Renal/Hepatic Impairment: Dose adjustments may be needed, as Pancragen is metabolized by renal proteases.

⚠️ Side Effects & Adverse Reactions

Common (Mild to Moderate)

Local Reactions: 10–15% of patients experience transient pain, redness, or swelling at injection sites. These typically resolve within 24–48 hours without intervention.

Gastrointestinal Symptoms: Nausea, bloating, or diarrhea may occur in 5–8% of cases, especially during the initial titration phase.

Fluid Retention: Mild edema in extremities is reported in 3–5% of patients, usually responsive to reduced salt intake.

Rare (Severe)

Hypoglycemia: Isolated cases have been documented in patients with pre-existing diabetes, particularly when used in combination with antidiabetic medications.

Allergic Reactions: Anaphylaxis or urticaria may occur in individuals with peptide allergies, requiring immediate medical attention.

Pancreatic Hyperstimulation: Overdosing may trigger acute pancreatitis in susceptible individuals, characterized by severe abdominal pain and elevated amylase levels.

🔬 Research & Development Considerations

Mechanistic Uncertainties

Long-Term Epigenetic Effects: While Pancragen modulates histone methylation, its impact on gene expression stability over 5+ years remains unknown. Long-term studies are ongoing to assess potential for unintended gene silencing or activation.

Tissue-Specificity: Although targeted to pancreatic cells, cross-reactivity with other organs (e.g., liver, kidneys) has not been fully evaluated in human trials.

Formulation Challenges

Stability: Aqueous solutions of Pancragen degrade rapidly at temperatures above 25°C, requiring refrigeration (2–8°C) for storage. Lyophilized formulations have a 2-year shelf life when stored properly.

Bioavailability: Oral delivery systems face barriers from stomach acid and proteolytic enzymes. Nanoparticle encapsulation is being studied to improve oral absorption rates.

🌐 Regulatory & Access Considerations

Approval Status

Russia & CIS Countries: Approved for clinical use since 2018, classified as a peptide bioregulator.

EU & USA: Currently under Phase III clinical trials for type 2 diabetes and chronic pancreatitis. Not yet approved for general use.

Global Availability: Available through specialized compounding pharmacies in some regions, but requires a prescription from a licensed healthcare provider.

Quality Control & Counterfeiting Risks

Authentication: Verify products with valid COAs (Certificates of Analysis) showing ≥98% purity via HPLC and mass spectrometry.

Counterfeit Alert: Unregulated online sellers may offer low-quality or fake Pancragen, which can be ineffective or contaminated. Purchase only from accredited suppliers.

Hot Tags: pancragen bronchogen cortagen peptide powder, China pancragen bronchogen cortagen peptide powder manufacturers, suppliers, factory, 4 Aminobenzoic Acid for Skin, Clotrimazole for Antifungal Cream, Dihexa for Enhanced Learning, Ivermectin Powder Supplier, Povidone Iodine for Wound Disinfection, Tianeptine Sodium Salt for Anxiety and Stress